Achillion Pharmaceuticals, Inc.
300 George Street
254 articles about Achillion Pharmaceuticals, Inc.
1/10/2020The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020
European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor– Phase 3 PNH initiation planned early 2020 –
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the European Medicines Agency (EMA) has granted access to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who are not adequately responding to a C5 inhibitor.
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor.
Reached an agreement to be acquired by Alexion; transaction expected to close in first half of 2020
Achillion Pharmaceuticals, Inc. announced the acceptance of two abstracts about danicopan, the Company’s lead oral factor D inhibitor, for poster presentation at the 61st American Society of Hematology Annual Meeting to be held in Orlando, Florida from December 7-10, 2019.
Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for Factor D inhibition in additional alternative pathway complement-mediated rare diseases
The deal is expected to close in the first half of 2020.
Achillion’s ACH-5228 Achieves Positive Results In Phase 1 Multiple Ascending Dose Study In Healthy Volunteers
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, announced results from their Phase 1 multiple ascending dose study with ACH-5228 outside of the United States.
2/15/2019Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately.
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
9/17/2018Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
Achillion Initiates Phase I First-in Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
This initial phase 1 trial is a randomized, placebo-controlled, single-ascending dose study of ACH-5228 administered to healthy volunteers.
Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy (C3G) and the Initiation of a Phase 1 Extended-Release Bioavailability Study
This designation may provide, under specified conditions, for a seven-year marketing exclusivity period, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.
The offering is expected to close on November 20, 2017, subject to the satisfaction of customary closing conditions.
Greater than 50% improvement in proteinuria (albumin to creatinine ratio) after 14 days of oral dosing with ACH-4471.
Achillion will not sell any shares or receive any proceeds from the offering, and the total number of shares of its outstanding common stock will not change as a result of the offering.
The EMA Committee for Orphan Medicinal Products also issued a positive opinion on ACH-4471 for orphan status in the European Union for the treatment of PNH.